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Abstract
The porcine parvovirus (PPV) VP2 protein was expressed in an insect-baculovirus cell system and was purified using
Ni-NTA affinity column chromatography. The recombinant 6-His-tagged VP2 protein with molecular mass (Mr) of
about 64 kDa was detected by anti-his antibody and anti-PPV serum. Electron microscopy showed that the purified
VP2 protein assembled into spherical particles with diameters ranging from 20 to 22 nm. The expressed VP2 was
antigenically similar to the native capsid protein according to HA and a Western blotting assay performed with
polyclonal antibodies collected from an outbreak of PPV in one farm. This study provides a foundation for the
application of VP2 protein in the clinical diagnosis of PPV or in the vaccination against PPV in the future.
1. Introduction
Porcine parvovirus (PPV) causes reproductive failure in
pregnant sows. The infection occurs without clinical
symptoms in adults; however, the virus can cross the pla-
cental barrier during the infection and cause the death of
the fetuses, stillbirths and return to estrus [1]. More
recently, PPV has gained importance as an agent able to
increase the effects of porcine circovirus type 2 infection
in the clinical course of postweaning multisystemic wast-
ing syndrome (PMWS) [2,3], which is a significant dis-
ease in global swine production [4]. Widespread
vaccination has been proposed as a cost-effective method
to reduce the economical losses due to the endemic and
worldwide prevalence of this virus [5,6].
PPV is a small, non-enveloped, single-stranded, nega-
tive-sense DNA virus. Capsids of PPV are assembled
from three viral proteins (VP1, VP2, and VP3). The
major structural protein, VP2 is the main target for neu-
tralizing antibodies in PPV [7,8]. When VP2 was
expressed in large amounts using the baculovirus
expression vector system, it assembled into virus-like
particles (VLPs) similar in size and morphology to the
original virions [7]. PPV VP2 VLPs induced antibodies
against PPV in immunised pigs [7] and rabbits [9]. PPV-
cell or tissue-tropism determinants, host-range determi-
nants, and determinants that confer hemagglutination
properties have all been shown to be located in the cap-
sid proteins [10-12]. It is noted that PPV VP2 was
expressed by Lu et al. (2002) in pFastBac I and by Si et
al. (2006) in pFastBacDUAL using insect cell-baculovirus
systems and both groups demonstrated a 64 kDa band
by Western-blot analysis.
Because VP2 is the main structural protein of PPV
and constitutes most of the viral capsid, VP2 produced
in vitro can self assemble into virus-like particles [13].
PPV VP2 VLPs exhibited positive immunoreactivity for
PPV in a commercial ELISA [14]. Rueda et al. (2000)
showed that contaminant baculovirus could be inacti-
vated in preparations of PPV VP2 VLPs while retaining
physical and immunological properties. VP2 VLPs have
been produced and purified using a specific affinity
Immobilized Metal Affinity Chromatography (IMAC)
system for other parvoviruses such as B19 [15] and for
infectious bursal disease virus [16]. To facilitate the use
of PPV VP2 for diagnosis and vaccination, the current
study attempted to identify an improved procedure for
producing VP2 in vitro and for purifying this fusion
protein.
There are many advantages to the use of VLPs in vac-
cines and for diagnosis. Compared to inactivated virus,
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the propagation of infectious virus, there is no risk of
virus transmission or infection, production levels are
much higher, production is cost effective, and VLPs are
generally stable. The authors have previously expressed
PPV VP2 in E. coli using the plasmid pET-32a (+) [17].
VP2 expressed in bacteria had similar antigenicity to
native PPV VP2, as determined by Western blot analysis
using polyclonal antibodies from pigs vaccinated against
PPV [17]. PPV VP2 expressed in bacteria appears to
have good immunogenicity, this is better for using as
vaccine than the use as diagnosis antigen, for the anti-
body for E. coli in sera effects the ELISA assay. This
provide us a compelling reason for expressing PPV VP2
in a baculovirus system, although baculovirus expression
systems are likely to be more costly than bacterial
expression systems for producing viral proteins and may
present difficulty in purifying expressed proteins from
insect cell and baculovirus constituents. PPV VP2 has
been expressed in insect cell-baculovirus systems by a
number of other groups previously [7,9,14,15]. PPV VP2
expressed by baculovirus in sf9 cells produced VLPs
[7,9,14,15]. PPV VP2 VLPs induced antibodies against
PPV in immunised pigs [7]and rabbits [14]. PPV VP2
VLPs exhibited positive immunoreactivity for PPV in a
commercial ELISA [15]. Rue d ae ta l .[ 1 ]s h o w e dt h a t
contaminant baculovirus could be inactivated in pre-
parations of PPV VP2 VLPs while retaining physical and
immunological properties. It is noted that PPV VP2 was
expressed by [15] in pFastBac I and by Si et al. [9] in
pFastBacDUAL using insect cell-baculovirus systems
and both groups demonstrated a 64 kDa band by Wes-
tern-blot analysis. VLPs produced in baculovirus-
infected insect cells could then be used as a vaccine or
as a diagnostic agent to detect the antibody produced by
PPV infection or vaccination [18]. Baculovirus-infected
insect cells have been used to produce VP2 VLPs of
infectious bursal disease virus [19], and parvoviruses
including PPV [14] and B19 [15]. To further facilitate
the use of PPV VP2 for diagnosis and vaccination, the
goal of the current study was to find an improved pro-
cedure for expressing PPV VP2 in vitro and to purify
the fusion protein.
2. Materials and methods
2.1. Cells, virus, and reagents
Strain 20-06 of PPV was isolated from a dead fetus
delivered from a sow diagnosed with reproductive fail-
ure. HRP-labeled anti-pig serum was purchased from
Sigma (St. Louis, Missouri, USA). Ni-NTA His Bind
resin was obtained from Invitrogen (Carlsbad, California,
USA). Prestained protein ladder was purchased from
Fermentas International Inc. (Burlington, Canada).
Swine anti-PPV serum samples, with serum
neutralization titer, were obtained from the Harbin
Veterinary Research Institute, CAAS. The serum sam-
ples were collected from an outbreak of PPV in 2008 in
one farm in Heilongjiang Province.
2.2. Construction of recombinant plasmids and
recombinant bacmid
Genomic DNA was extracted from the cell-cultured
strain 20-06 of PPV by the classical phenol-chloroform
extraction method and was used as a template to
amplify the VP2 fragment by PCR. The PPV VP2 gene
was amplified with the primers PPV-VP2 FD (TATG-
GATCCGATGAGTCATCATCACCATCACCATAGT-
GAAAATGTGGAACAAC) and PPV-VP2 RV (GCGT
CGACTATGAGTTAGAGTTTGTATTAG). The under-
lined nucleotides represent BamHI and SalI restriction
sites, respectively. The PCR products were digested with
BamHI and SalI and subsequently cloned into the corre-
sponding restriction sites of the pFastbac1 vector to pro-
duce the recombinant plasmid, pFastPVP2. The insert
of the recombinant plasmid was confirmed by DNA
sequencing.
After the recombinant pFastPVP2 donor plasmid was
determined to be correct, the DNA was transformed
into DH10Bac™ for transposition into the bacmid. The
transposition assay and subsequent transfection steps
were the same for all vectors. White colonies contained
the recombinant bacmid, and therefore were selected for
isolation of recombinant bacmid DNA. Before DNA was
isolated, candidate colonies were streaked to ensure they
were truly white. Bacmid DNA (B-pFastPVP2) was
extracted by the phenol-chloroform extraction method.
The recombinant Bacmid (B-pFastPVP2) was then ana-
lyzed by PCR.
2.3. Expression of the VP2 protein in sf9 cells
The recombinant baculoviruses, containing the coding
sequences of VP2 with the polyhistidine tag at the N-
terminus, were generated by using the Bac-to-BacTM
system (Invitrogen; Luckow et al., 1993). Propagation of
the recombinant virus was performed according to stan-
dard procedures (Summers et al., 2006). For production
of the recombinant VP2 proteins, sf9 (Spodoptera frugi-
perda) cells were grown in 2-l Erlenmeyer flasks on
orbital shakers (120 rpm) to a concentration of about
2×1 0
6 cells per ml of culture medium (30 ml growing
volume) and infected with the recombinant viruses at a
multiplicity of infection (MOI) of 2-3. At 72 h postinfec-
tion (p.i.), cells were collected and processed as
described below. The infected cells were collected by
low-speed centrifugation at 3500 × g (Hermle Labor-
technik, Wehingen, Germany; swing-out rotor 4 × 750
ml) for 15 min at 4°C and solubilized in 30 ml of ice-
cold lysis buffer [20 mM Tris, 0.3 M NaCl, 1.0% (v/v)
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(about 20 × 10
6 cells/ml). The crude cell lysate was clar-
ified by high-speed centrifugation at 23,400 × g (Sorvall,
Thermo Fisher Scientific, Waltham, MA; GSA rotor) for
20 min at 4°C. The supernatant fraction was collected,
and the soluble recombinant protein products purified
by IMAC as described below.
2.4. Purification of PPV VP2 protein
Cells were harvested at different times after infection,
centrifuged at 200 × g for 15 min, and resuspended in
25 mM Na2HCO3,p H8 . 3 ,a tad e n s i t yo f2×1 0
7 cells/
ml; lysis was allowed to occur for 20 min. Afterward, cell
debris was removed by centrifugation at 10,000 g for
15 min. The recombinant fusion protein VP2 was puri-
fied by IMAC. The clarified lysate was incubated with
3 ml of pre-equilibrated Ni2+- Streamline Chelating
GelTM (Amersham Biosciences, Piscataway, NJ) on a
rotating wheel for 16 h at 4°C, and was then placed in a
10-ml chromatography column (PolyPrep 0.8 by 4 cm;
BioRad, Hercules, CA). Weakly bound and contaminating
proteins were washed from the chelating gel by using 10×
the column volume (20 mM Tris, 0.3 M NaCl, 20 mM
imidazole, pH 7.4). The recombinant polyhistidine-
tagged protein products were finally eluted from the
packed bed with 3-4× the column volume (20 mM Tris,
0.3 MNaCl, 500 mM Mimidazole, pH 7.4). One-ml frac-
tions were collected, and the protein contents were ana-
lyzed using a NanoDrop ND-1000 spectrophotometer
(NanoDrop Technologies, Wilmington, DE).
2.5. SDS-PAGE and Western blotting
T h ep u r i t ya n dt h ea p p a r e n tm o l e c u l a rw e i g h to ft h e
recombinant VP2 specific proteins were assessed by
sodium dodecyl sulfate polyacrylamide gel electrophor-
esis (SDS-PAGE) and immunoblot analysis. The purified
proteins were separated by SDS-PAGE and were either
stained with Commassie Brilliant Blue or were trans-
ferred onto nitrocellulose membranes using a wet trans-
fer cell for Western blotting. The protein expressed 0 to
5 days after insect cells were challenged was obtained
for Western blotting. The membranes were blocked
with 5% skimmed milk in TBS-T (50 mM Tris-HCl, 150
mM NaCl; 0.05% Tween 20, pH 7.5) for 1 h at room
temperature (RT). Swine anti-PPV sera (1:1000 dilution)
or anti-His monoclonal antibody (1:5000 dilution) was
added to the membranes and shaken overnight at 4°C.
The membranes were then washed three times (5 min
each time) with TBS-T. Secondary antibody, either anti-
swine or anti-mouse at 1:5000 dilution, was then added
and incubated for 1 h. After the membranes were
washed, 3,3’-diaminobenzidine (DAB) was added for col-
our development.
2.6. Hemagglutination assay
Following the method of Senda et al. [20], two-fold dilu-
tions of samples of VP2 protein were prepared, mixed
with guinea pig red blood cells, and added to the wells
of a 96-well plate. After 60 minutes at 37°C, the wells
were photographed.
3. Results
3.1 Construction of recombinant plasmids pFastpVP2 and
recombinant bacmid
The recombinant plasmids pFastpVP2 and B-pFastpVP2
were identified by BamHI and SalI enzyme digestion.
The fragments were about 1800 bp and 4775 bp, respec-
tively, which conformed to the expected sizes (Figure 1).
Recombinant bacmid was identified by PCR with the
primers PPV-VP2 FD and PPV-VP2 FD. The fragment
was about 1840 bp.
3.2 Expression and purification of polyhistidine-tagged
VP2 of PPV
We have previously shown that formation of chimeric
VLPs of PPV fusion constructs is feasible in pET-PPV
with E. coli cells (Qi T et al., 2009). The recombinant
baculoviruses encoding the structural proteins VP2 of
PPV N-terminally fused to a polyhistidine tag (6 × his)
were engineered to simplify the overall purification pro-
cess of these the viral antigens. The recombinant bacu-
loviruses were used for infection of Sf9 insect cells
Figure 1 Restriction endonuclease digests of PPV VP2 plasmid
DNA. Products produced by restriction enzyme digestion of the
vector plasmid (lane 1), the PCR product of the VP2 gene (lane 2),
and the recombinant plasmid (lane 3). Lane M shows the DL15000
DNA marker.
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insect cells were collected and solubilized by treatment
with a non-ionic detergent. The cell lysates were clari-
fied by centrifugation, and the viral proteins were finally
extracted from the cytoplasmic extracts by IMAC
(Ni2+). After isolation, the recombinant VP2 specific
fusion proteins were analyzed by SDS-PAGE, Western-
blotting, and hemagglutination assay (HA).
3.3 SDS-PAGE and Western blotting
The VP2 protein was identified with the SDS-PAGE and
Western blotting. To confirm the identity of his-tagged
VP2, the purified fusion protein was subjected to Wes-
tern blot assay using PPV-positive pig sera. The polyco-
lonal antibodies recognized his-tagged VP2, and the
band had the appropriate molecular weight. Immuno-
blot of these membranes using anti-PPV antibodies
showed that the fusion protein had epitopes derived
from PPV. The Western blots of purified protein
obtained 0 to 5 days after insect cells were challenged
indicated that the protein was expressed on day 4 and 5
(Figure 2).
To purify the fusion protein (his-tagged VP2), Ni-
NTA agarose were used to finish the SDS-PAGE and
Western blotting. The results showed that the target
protein could be conjugated to the resin. A single band
was detected by SDS-PAGE Western blotting (Figure 3).
To confirm the identity of VP2 minus the his-tag tail,
the purified VP2 without a His-Tag was subjected to
Western blotting assay using PPV-positive pig sera. The
polyclonal antibodies recognized VP2 without a His-
Tag, and the band had a molecular weight of 64 KDa.
The assay therefore provided evidence that the protein
could be used as an efficient immunological reagent.
This conclusion was supported by the HA (see next two
sections).
3.4 HA
Sample VP2 protein caused hemagglutination when
diluted up to 1:8,192 (Figure 4). Therefore, the HA titer
of this protein stock was 8,192.
4. Discussion
Currently, vaccines against PPV are produced by chemi-
cally inactivating isolated virus particles grown in primary
cell cultures of porcine origin. The method is both labor
intensive and costly, with the additional hazard of requir-
ing the handling of large quantities of infectious virus
[21]. Economic and safety considerations, as well as prac-
tical limitations associated with low yields of PPV parti-
cles from in vitro cultures, led us to the investigate
recombinant sub-unit vaccines for PPV. The VP2 protein
of PPV had been previously shown to self-assemble into
virus-like particles when expressed in insect cells by
baculovirus infection [7]. In addition, the virus-like parti-
cles of PPV were found to be highly immunogenic, and
breeding sows were protected against reproductive failure
in PPV challenge experiments [22]. Nonetheless, baculo-
virus-based systems for the production of recombinant
proteins are still technically demanding, requiring sterile
bioreactors that may be prohibitively costly for the pro-
duction of vaccines for farm animals. Given that PPV
causes serious economic losses for swine producers,
Figure 2 Western blot analysis of 6-His-tagged recombinant
PPV VP2 protein expressed at different times after insect cells
were infection with baculovirus. lane 1, the protein expressed in
insect cells challenged with negative baculovirus; lanes 2 to 6, the
protein expressed 1 to 5 days after insect cells were challenged
with recombinant baculovirus; M, prestained protein ladder. The first
antibody is PPV-positive pig sera, the second antibody is horseradish
peroxidase-conjugated rabbit anti-pig antibody.
Figure 3 Western blot analysis of expressed VP2.M :p r e s t a i n e d
protein ladder, 1: the purified VP2 without the His-Tag, 1: the
control of VP2 before induction. The first antibody is PPV-positive
pig sera, the second antibody is horseradish peroxidase-conjugated
rabbit anti-pig antibody.
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for producing vaccines and diagnosing the disease is
warranted.
This paper describes a method for producing the VP2
protein of PPV in an insect-baculovirus cell system.
After expression was optimized, a his-tagged VP2 was
obtained. The paper also describes an alternative
method (IMAC) for efficient recovery of PPV VP2 and
for purifying the protein using a Ni-NTA affinity col-
umn chromatography. This purification method avoids
time-consuming ultracentrifugation steps such as
sucrose gradient or cesium chloride gradient centrifuga-
tion. When larger amounts of recombinant proteins are
needed, the purification process could be easily scaled-
up by using an expanded-bed adsorption column techni-
que. The virus-like particles formed by the fusion pro-
tein had high HA titer, could be useful as antigens for
detecting PPV and could be useful for the development
of a vaccine against PPV that is effective but less expen-
sive than current vaccines [23].
The authors have previously expressed PPV VP2 in E.
coli using the plasmid pET-32a (+) [17]. VP2 expressed
in bacteria had similar antigenicity to native PPV VP2,
as determined by Western blot analysis using polyclonal
antibodies from pigs vaccinated against PPV [17].
Although PPV VP2 expressed in bacteria appears to
have good immunogenicity, it is better for using as vac-
cine than the use as diagnosis antigen, for the antibody
for E. coli in sera bothers the ELISA assay. This provide
us a compelling reason for expressing PPV VP2 in a
baculovirus system. The authors note a number of other
studies where recombinant PPV VP2 expressed in bacu-
lovirus has been engineered with other viral antigens or
immunogenic epitopes to produce multivalent vaccine
candidates. The current diagnostic tests and vaccines for
PPV are well established and considered to be adequate
for most practical purposes; therefore the authors would
like to demonstrate that any new diagnostic technology
using recombinant PPV VP2 has advantages over cur-
rent diagnostic tests and that any new vaccines against
PPV using VP2 are superior to current vaccines in the
future.
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